These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1329 related items for PubMed ID: 19007692
1. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy. Cuoco FA, Spencer WH, Fernandes VL, Nielsen CD, Nagueh S, Sturdivant JL, Leman RB, Wharton JM, Gold MR. J Am Coll Cardiol; 2008 Nov 18; 52(21):1718-23. PubMed ID: 19007692 [Abstract] [Full Text] [Related]
2. Ventricular arrhythmia following alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Noseworthy PA, Rosenberg MA, Fifer MA, Palacios IF, Lowry PA, Ruskin JN, Sanborn DM, Picard MH, Vlahakes GJ, Mela T, Das S. Am J Cardiol; 2009 Jul 01; 104(1):128-32. PubMed ID: 19576333 [Abstract] [Full Text] [Related]
4. Implantable cardioverter-defibrillators in patients with hypertrophic cardiomyopathy -- dilemmas and difficulties. Przybylski A, Małecka L, Pytkowski M, Chojnowska L, Lewandowski M, Sterliński M, Maciag A, Ruzyłło W, Szwed H. Kardiol Pol; 2005 Oct 01; 63(4):391-7; discussion 398. PubMed ID: 16273479 [Abstract] [Full Text] [Related]
5. [The implantable cardioverter-defibrillator and hypertrophic cardiomyopathy. Experience at three centers]. Marín F, Gimeno JR, Payá E, García-Alberola A, Pérez-Alvarez L, Fernández X, de la Morena G, Sogorb F, Castro-Beiras A, Valdés M, Martínez JG, Monserrat L. Rev Esp Cardiol; 2006 Jun 01; 59(6):537-44. PubMed ID: 16790196 [Abstract] [Full Text] [Related]
9. Transcoronary ablation of septal hypertrophy does not alter ICD intervention rates in high risk patients with hypertrophic obstructive cardiomyopathy. Lawrenz T, Obergassel L, Lieder F, Leuner C, Strunk-Mueller C, Meyer Zu Vilsendorf D, Beer G, Kuhn H. Pacing Clin Electrophysiol; 2005 Apr 01; 28(4):295-300. PubMed ID: 15826262 [Abstract] [Full Text] [Related]
10. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy. Maron BJ, Spirito P, Ackerman MJ, Casey SA, Semsarian C, Estes NA, Shannon KM, Ashley EA, Day SM, Pacileo G, Formisano F, Devoto E, Anastasakis A, Bos JM, Woo A, Autore C, Pass RH, Boriani G, Garberich RF, Almquist AK, Russell MW, Boni L, Berger S, Maron MS, Link MS. J Am Coll Cardiol; 2013 Apr 09; 61(14):1527-35. PubMed ID: 23500286 [Abstract] [Full Text] [Related]
15. Long-term outcome of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: a word of caution. ten Cate FJ, Soliman OI, Michels M, Theuns DA, de Jong PL, Geleijnse ML, Serruys PW. Circ Heart Fail; 2010 May 14; 3(3):362-9. PubMed ID: 20332420 [Abstract] [Full Text] [Related]
16. Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. Valeti US, Nishimura RA, Holmes DR, Araoz PA, Glockner JF, Breen JF, Ommen SR, Gersh BJ, Tajik AJ, Rihal CS, Schaff HV, Maron BJ. J Am Coll Cardiol; 2007 Jan 23; 49(3):350-7. PubMed ID: 17239717 [Abstract] [Full Text] [Related]
17. Alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy: low incidence of sudden cardiac death and reduced risk profile. Jensen MK, Prinz C, Horstkotte D, van Buuren F, Bitter T, Faber L, Bundgaard H. Heart; 2013 Jul 23; 99(14):1012-7. PubMed ID: 23644300 [Abstract] [Full Text] [Related]
18. Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy. Vieira AP, Adragão PP, Santos KR, Morgado FB, Cavaco DM, Rossi R, Abecasis M, Neves JP, Bonhosrst D, Gomes JL, Gomes RS. Rev Port Cardiol; 2005 Mar 23; 24(3):407-15. PubMed ID: 15929624 [Abstract] [Full Text] [Related]